Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Sustained Emotionally coloured Machine-human Interaction using Nonverbal Expression (SEMAINE)

Framework: FP7 — Cooperation
Programme: Information and Communication Technologies
Destination: Cognitive systems, interaction, robotics
Action type: Collaborative project
Countries involved: Germany,United Kingdom,United Kingdom,Netherlands,France,Germany,France
Call:  (FP7-ICT-2007-1, 2007)
Start date: 2008-01-01
End date: 2010-12-31
Duration (months): 36.0
Total project cost (EUR): 3602849.0
EU funding (EUR): 2750000.0
Participants: 7
Project status: CLOSED

The aim of the SEMAINE project is to draw together the current research on non-verbal signs and to produce a system that capitalises on them to achieve genuinely sustained, emotionally coloured interactions between a person and a machine. To do that, it develops an idea which was introduced in the FP5 project ERMIS and pursued in HUMAINE. The idea is to build a ‘Sensitive Artificial Listener’, or SAL for short, which interacts with human beings in a shallow but emotion-rich way, using interactions observed in chat shows and at parties as a model. The verbal capabilities of such a system are very limited and superficial, similar to ‘chatbots’ from ELIZA on. Like them, it uses rules to respond to what a listener says without understanding the content in any depth. Unlike chatbots, however, a SAL system has sophisticated, robust, real-time multi-modal interaction capabilities – in an ongoing interaction, it detects the emotional colouring communicated by the user, and adapts its responses to that. In SAL, the system's responses are themselves emotionally loaded, and are chosen to propel the user towards an emotional state that the system currently ‘wants’ the user to be in.

Keywords: non-verbal interaction,emotion-oriented computing,multimodal interaction
European Facility for innovative reactor and transmutation neutron data (EUFRAT)

Framework: FP7 — Euratom
Programme: Nuclear fission and radiation protection
Theme: Research infrastructure
Destination: Infrastructures
Action type: Coordination and support actions
Countries involved: European organisations area
Call:  (FP7-Fission-2007, 2007)
Start date: 2008-11-01
End date: 2012-10-31
Duration (months): 48.0
Total project cost (EUR): 502908.09
EU funding (EUR): 502908.0
Participants: 1
Project status: CLOSED

The Neutron Physics Unit of the EC-JRC-IRMM (Geel, Belgium) is equipped with a unique scientific infrastructure of European relevance. This research infrastructure, which to a large extent is operating for highly accurate neutron cross-section measurements, includes two accelerators facilities: GELINA is a 150 MeV electron accelerator serving as strong white neutron source for high-resolution neutron time-of-flight measurements. The 7 MV Van de Graaff facility is an electrostatic accelerator for the production of continuous and pulsed proton-, deuteron- and helium ion beams which is serving as a source of well characterised quasi-monoenergetic neutrons. The measurement capabilities at both facilities, which are complementary, cover the whole energy range from a few meV to about 24 MeV. A Transnational Access project NUDAME has been running within the framework of the FP6 Euratom programme until March 31, 2008. This NUDAME project has proved to be successful with a high quality of research proposals and a large proportion of new users that were attracted. In total, 22 experiments were proposed, exceeding about 2.5 times the beam time which could be provided. 18 proposals were approved by the Programme Advisory Committee of NUDAME, but with a drastically reduced beam time. 90% of the supported users are first-time users. The large demand for experimental opportunities at the scientific infrastructure of IRMM shows clearly the need for support of scientific groups from the European Union. It is the objective of this proposal to offer for the next four years a total of 4500 hours of additional data-taking hours for external users. Experiments in the thematic area addressed in the 7th Euratom Fission Framework Programme can be performed provided that the experimental infrastructure can offer a significant added value to the project. Selection of the supported experiments is based on peer review.

Keywords: neutron data,cross-section measurements,accelerators,neutron sources,time-of-flight,nuclear physics,neutron physics
Water in Industry, Fit-for-Use Sustainable Water Use in Chemical, Paper, textile and Food Industry (AQUAFIT4USE)

Framework: FP7 — Cooperation
Programme: Environment (including Climate Change)
Destination: Environmental technologies
Action type: Collaborative project
Countries involved: Netherlands,Germany,Spain,Belgium,Spain,France,Slovenia,Italy,France,Denmark,Netherlands,Netherlands,Belgium,Czechia,Sweden,Spain,Poland,Germany,Belgium,Czechia,United Kingdom,Germany,Italy,Belgium,Germany,Germany
Call:  (FP7-ENV-2007-1, 2007)
Start date: 2008-06-01
End date: 2012-08-31
Duration (months): 51.0
Total project cost (EUR): 14580950.4
EU funding (EUR): 9650000.0
Participants: 36
Project status: CLOSED

Sustainable water use in industry is the goal of AquaFit4Use, by a cross-sectorial, integrated approach. The overall objectives are: the development and implementation of new, reliable, cost-effective technologies, tools and methods for sustainable water supply, use and discharge in the main water consuming industries in order to significantly reduce water use, mitigate environmental impact and produce and apply water qualities in accordance with industrial own specifications (fit - for - use) from all possible sources, and contributing to a far-going closure of the water cycle in a economical, sustainable and safe way while improving their product quality and process stability. The 4 pillars of the project are Industrial Water Fit-for-use, Integrated water resource management, Strong industrial participation and Cross-sectorial technologies and approach. Water fit-for-use is the basis for sustainable water use; the integrated approach a must. Tools will be developed to define and control water quality. The heart of AquaFit4Use however is the development of new cross-sectorial technologies, with a focus at biofouling and scaling prevention, the treatment of saline streams, disinfection and the removal of specific substances. By intensive co-operation between the industries, the knowledge and the technologies developed in this project will be broadly transferred and implemented. This AquaFit4Use project is based on the work of the Working group "Water in Industry" of the EU Water Platform WSSTP; 40 % of the project partners of AquaFit4Use were involved in this working group. The expected impacts of AquaFit4Use are: A substantial reduction of fresh water needs (20 to 60%) and effluent discharge of industries; Integrating process technologies for further closing the water cycles; Improved process stability and product quality in the different sectors and strengthening the competitiveness of the European Water Industry.

Keywords: industrial water,fit-for-use,paper,food,chemistry,textiles,water treatment,modeling,water quality,water quality definition
Immersive interface technologies for life-cycle human-oriented activities in interactive aircraft-related virtual products (VISION)

Framework: FP7 — Cooperation
Programme: Transport (including Aeronautics)
Destination: Aeronautics and air transport
Action type: Collaborative project
Countries involved: Greece,Germany,France,Germany,Finland,Austria
Call:  (FP7-AAT-2007-RTD-1, 2007)
Start date: 2008-11-01
End date: 2011-06-30
Duration (months): 32.0
Total project cost (EUR): 2197252.0
EU funding (EUR): 1485714.0
Participants: 6
Project status: CLOSED

Although Virtual Reality (VR) has demonstrated a significant potential for interactive applications on product and process development, the proven quality of the underlying technologies is still far from satisfying the real-life needs of aerospace industrial practice. VISION aims to specify and develop key interface features in fundamental cornerstones of VR technology, namely in immersive visualization and interaction, so as to improve the flexibility, the performance and cost efficiency of human-oriented life cycle procedures, related to critical aircraft-related virtual products (e.g. virtual cockpit, virtual cabin etc.). The upstream research roadmap of VISION will involve a) specific human-oriented developments on simulation features, such as the visual perception, the real-time rendering, the markerless body tracking, the smart objects interaction, the interaction metaphors, b) an integration of the features in a common IT platform, and c) a validation based on test cases focused on specific aircraft-related virtual products. The achievements of VISION will enhance the credibility of the human-in-the loop aircraft-related VR simulations. They will further enhance the engineering context of the aircraft-related virtual products by enabling their increased use for activities, such as design verification, ergonomics validation, specifications of equipment displays, operational and situational training. The VISION project aims to develop new technology in support of the design and ‘virtual prototyping’ of critical aircraft-related products. It will improve the human-oriented functionality and usage of these virtual products along their life-cycle. Thus, it addresses the "Design Systems & Tools" and "Human Factors" Call topics. The Consortium of VISION includes representatives from all major stakeholders, including end users, research partners and VR IT vendors. VISION is supported by the European Aeronautics Science Network (EASN)

Keywords: virtual cockpit,virtual cabin,immersion,interaction,visualization
COURAGE in Europe - COllaborative Research on AGEing in Europe (COURAGE IN EUROPE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Italy,Switzerland,Finland,Spain,Spain,Italy,Poland,Poland
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-05-01
End date: 2012-12-31
Duration (months): 44.0
Total project cost (EUR): 3795824.8
EU funding (EUR): 2999992.0
Participants: 13
Project status: CLOSED

The European Commission has identified the challenge of population ageing as the most pressing policy issue in the 21st century. As Europeans live longer and disabilities in this population increase, valid and comparable longitudinal data on their health is essential for evidence based policy making. Valid data requires better measurement instruments and methodologies for longitudinal and cross-population comparative analyses. After an in-depth critique of existing ageing studies, COURAGE in Europe will develop, and validate in three countries, measures of health and health-related outcomes for an ageing population. These measures will be grounded in the WHO’s International Classification of Functioning, Disability and Health (ICF). The ICF offers the only scientifically valid framework for evidence-based measurement of non-fatal health outcomes. We also propose to disentangle the confusion found in current ageing studies between objective states of health and subjective conditions of quality of life and well-being. These elements must be measured independently and against the background of the clear conceptual framework of health. COURAGE in Europe will enhance the scientific study of ageing by developing a tool to demonstrate the relevance to the ageing population of two environmental factors: the built environment and social networks. In sum, COURAGE in Europe is not proposing another ageing study, but the development of a tool to measure of health and health-related outcomes, for an ageing population, that offers objective and evidence-based prevalence trends, and which relates these to both quality of life and well-being outcomes as well as to the role of health determinants such as the built environment and social networks. Understanding ageing and its determinants will have a considerable impact on public health policies by identifying strategies for intervention.

Keywords: health outcome measures,ageing,icf,policy,health,quality of life,well-being,functioning,disability,built environment,social networks,population survey
Optimization of stem cell therapy for clinical trials of degenerative skin and muscle diseases (OPTISTEM)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Italy,Switzerland,United Kingdom,France,United Kingdom,United Kingdom,Italy,Spain,Germany,Germany,United Kingdom
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-01-01
End date: 2013-12-31
Duration (months): 60.0
Total project cost (EUR): 16564311.99
EU funding (EUR): 11992312.0
Participants: 20
Project status: CLOSED

This proposal aims to develop and implement efficacy of clinical trials with adult, tissue stem cells for degenerative diseases of epithelia and skeletal muscle. Extraordinary progress in the understanding of several key features of stem cells has been rapidly translated into novel cell therapy protocols that have yielded positive results in pre-clinical models of genetic and acquired diseases and in the first clinical trials. Much remains to be done on the basic biology of stem cells to provide new tools for cell therapy trials. Also transplantation related issues, such as engraftment, angiogenesis, tissue remodeling and immune response remain to be addressed. In general, cell therapy necessitates a continuous cross-talk among biologists and clinicians as well as crossing boundaries among different tissues/diseases. Despite many structural and functional differences, epithelia and skeletal muscle share some key features such as spatially ordered cell architecture, centered on a supporting basal lamina to which stem cells are anchored. Indeed mutations in structural proteins linking the cell membrane to the basal lamina are responsible for similarly devastating diseases such as muscular dystrophies and epidermolysis bullosa. A multi-tissue approach allows jointly addressing and solving not only scientific and clinical problems but also regulatory and ethical issues related to these novel procedures. Finally, sharing high valued dedicated platforms such as large animal facilities and GMP cell culture facilities increases performance and reduces costs. Based on these considerations, a network of internationally recognized experts in muscle and epithelial cell biology, immunology, angiogenesis, and molecular pharmacology with two stem cell-based Companies has been assembled, creating a synergistic approach that will increase the chance of success for ongoing and future clinical trials with stem cells, that are integral part of this proposal.

Keywords: stem cells,clinical trials,degenerative diseases,muscle,epithelia,translation
Cis-regulatory logic of the transcriptional control in neural stem cells (CISSTEM)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: France,Germany,Italy,Germany,United Kingdom,Germany,United Kingdom
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-10-01
End date: 2012-03-31
Duration (months): 42.0
Total project cost (EUR): 4002786.88
EU funding (EUR): 2984169.0
Participants: 9
Project status: CLOSED

Neural stem cells (NSCs) have emerged as a major topic in neurobiology. The persistence of multipotent cells in the adult mammalian brain offers a realistic chance for the treatment of neurodegenerative diseases. It is thus crucial to understand NSCs from as many as possible angles (e. g. cellular and molecular biology), in order to better isolate and successfully manipulate them. CISSTEM presents a post-genomic systems biology approach, taking advantage of new computational and experimental tools to address the specification and maintenance of NSCs at the transcriptional/epigenetic level. CISSTEM is designed to unravel the basic principles of gene regulation in NSC, with a focus on cis-regulatory modules (CRMs). To do so we follow a multidisciplinary approach tightly interconnecting computational prediction and experimental validation in vitro and in vivo using different vertebrate models systems. Major intermediate objectives of this project are the prediction of relevant elements and the identification of the temporal, spatial and quantitative activities of predicted conserved regulatory motifs associated with NSC expressed genes. To achieve this goal, CISSTEM will i) Develop computational tools and resources for the in silico identification of CRMs and transcription factor binding sites (TFBSs) ii) Identify genomic regions functionally active in the NSC through direct mapping of DNase I hypersensitivity sites. Putative functional annotation to these sites will be implemented and conduct direct CRM prediction of the identified regions iii) Identify motifs/signatures over-represented in distal elements found around NSC expressed genes iv) Identify the elements acting as transcriptional enhancers and define their pattern of activities in different neural cell lines and in vertebrate animal model systems v) Disseminate the results of the project to the research community, biotech/pharmaceutical companies and the general public

Keywords: neural stem cells,systems biology,neurodegenerative diseases,ci-regulatory,bioinformatics,transcriptional regulatory networks
Combating incontinence, from basic science to clinical practice (INCOMB)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Sweden,United Kingdom,Netherlands,Switzerland,United Kingdom,Sweden,Portugal
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-12-01
End date: 2012-05-31
Duration (months): 42.0
Total project cost (EUR): 4035977.6
EU funding (EUR): 2908693.0
Participants: 10
Project status: CLOSED

Incontinence affects almost 66 million people in the European Union. The Over Active Bladder (OAB) symptom complex is one of the major causes for incontinence, with a large number of affected persons and immense associated health care costs. The causes for the over active bladder contractions, underlying the urinary urgency of OAB are unknown, and current treatments are only partially effective. This collaborative and translational project, involving interaction between experimental and clinical urology scientists will focus on OAB and will characterize the different interacting cellular components and signaling systems in the wall of normal urinary bladders and OAB. The release of local mediators in the bladder wall, the properties of a newly described cell type (the interstitial cells, which may play a role in bladder over activity), the sensory signaling pathways (TRPV1-receptors), the receptor interaction and cellular communication are considered in order to create an integrated view on the mechanisms of bladder over activity. A strong emphasis is put on interaction between basic science and clinical applications, using a translational approach involving both specific animal models and human tissue from patients with defined urodynamic information. Several ethical and logistic issues with the use of human tissue are specifically addressed. An important further aspect of the experiments on human tissue is a direct analysis of the links between genetic and the urodynamic data of the patients, using unique biobanks. This will allow us further insight into the mechanisms of disease and possibly to identify new therapeutic targets. In close collaboration with a small company, we will develop an innovative potential physical therapy to affect bladder function. We will develop novel pharmacotherapeutic strategies and diagnostic tools, based on the characterization of cell properties, gene expression, receptors signaling systems of the bladder wall.

Keywords: urinary incontinence,overactive,bladder dysfunction,understanding,treatment,mechanisms
Nucleobase derivatives as drugs against trypanosomal diseases (TRYPOBASE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Spain,United Kingdom,United Kingdom,Switzerland,Sweden,Uruguay,India
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-01-01
End date: 2012-06-30
Duration (months): 42.0
Total project cost (EUR): 3542209.6
EU funding (EUR): 2557187.0
Participants: 7
Project status: CLOSED

The protozoan diseases, leishmaniasis, African trypanosomiasis and Chagas’ disease are responsible for substantial global morbidity, mortality, and economic adversity, and in most countries, existing strategies for control and treatment are either failing or under serious threat. New tools for combating pathogenic protozoa and the development and exploitation of new drug targets are required. This proposal builds on several achievements and observations of the consortium in the area of nucleotide metabolism. •Pyrimidine and purine metabolism exhibits unique features in trypanosomes. •The identification of a unique enzyme involved in pyrimidine metabolism restricted to trypanosomes and essential for viability: the dimeric all-alpha dUTPase. •An exceptional collection of purine and pyrimidine analogues is available through the consortium for antiprotozoal screening and lead identification. •The consortium brings together an outstanding combination of expertise for drug discovery. The main objective is the identification of new purine and pyrimidine derivatives for the treatment of the leishmaniases and trypanosomiases. A two-pronged approach is proposed to discover new leads for the treatment of leishmaniasis and trypanosomiasis targeting nucleoside/ nucleotide metabolism. 1)The phenotypic approach exploring the potential of large collections of novel nucleobase derivatives against trypanosomal diseases. 2)The target-based approach specifically centred on the development of inhibitors of the enzyme deoxyuridine triphosphate nucleotidohydrolase. The trypanosomal enzyme shows structural and functional characteristics which differ profoundly from the mammalian counterpart. The aim is to identify potent inhibitors that are active against parasitic protozoa, active in rodent models of infection and have drug-like properties.

Keywords: drugs,nucleobase derivatives,leishmania,trypanosoma,deoxyuridine triphosphate nucleotidohydrolase